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Clinical Relevance of Mycobacterium szulgai
in The Netherlands
Jakko van Ingen,1,2 Martin J. Boeree,1 Wiel C. M. de Lange,1 Petra E. W. de Haas,2 P. N. Richard Dekhuijzen,1
and Dick van Soolingen2
1Department of Pulmonary Diseases, Radboud University Nijmegen Medical Center, Nijmegen, and 2National Mycobacteria Reference Laboratory,
National Institute for Public Health and the Environment, Bilthoven, The Netherlands
Background. The clinical relevance of Mycobacterium szulgai isolates is unknown, and available literature
focuses on case reports of M. szulgai disease. We assessed the clinical relevance of M. szulgai isolated from patients
in The Netherlands.
Methods. We reviewed medical files for all 21 patients in The Netherlands from whom M. szulgai was isolated
during 1999–2006, applying the diagnostic criteria of the American Thoracic Society for nontuberculous myco-
bacterial infection. Random amplified polymorphic DNA genotyping was performed using IS986, OPA-2, and
OPA-18 as primers.
Results. Of the 21 patients, 16 (76%) met the American Thoracic Society diagnostic criteria and were thus
likely to have M. szulgai disease. Pulmonary M. szulgai disease was the most common presentation, with extra-
pulmonary disease restricted to patients with an impaired systemic immunity. Although treatment regimens varied
in content and duration, the outcomes were mostly favorable. Both overtreatment and undertreatment were noticed.
Random amplified polymorphic DNA genotyping revealed a higher degree of interpatient variability, with limited
intrapatient variability, suggesting persisting monoclonal infection and good reproducibility. No genotype was
associated with clinical relevance.
Conclusions. Clinical isolation of M. szulgai generally represents true disease and demands careful follow-up.
Extrapulmonary disease occurs in patients with impaired immunity. Adherence to diagnostic guidelines can be
improved.
Mycobacterium szulgai is a slow-growing nontubercu-
lous Mycobacterium (NTM) that was first described in
1972 by Marks et al. [1] and that was named after Dr.
T. Szulga, who developed the lipid analysis method that
identified this NTM as a new species. NTMs are op-
portunistic pathogens, with local events (e.g., chronic
obstructive pulmonary disease [COPD] or healed tu-
berculosis) or systemic impaired immunity (e.g., receipt
of immunosuppressive medication, HIV infection, or
hematological malignancy) as the predisposing condi-
tion [2]. Pulmonary M. szulgai disease, which resembles
tuberculosis, is the most common presentation, al-
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though extrapulmonary and disseminated disease has
been recorded [1–6].
M. szulgai has been recovered from environmental
sources, including a snail, aquarium water, swimming
pool water, and tropical fish [3–6]. The environment
is the suspected source of human NTM infection [4,
7]. Therefore, M. szulgai disease has to be distinguished
from pseudoinfection because of the occasional pres-
ence of M. szulgai in clinical samples or contamination
of samples in the laboratory [2, 7].
The American Thoracic Society (ATS) published
guidelines for the diagnosis and treatment of NTM in-
fection [2]. The guidelines consist of clinical, radiologic,
and bacteriologic criteria and are summarized in fig-
ure 1.
We reviewed the medical files of all patients in The
Netherlands from whom M. szulgai was isolated during
the period from January 1999 through January 2006.
We assessed the frequency and clinical relevance of M.
szulgai isolation using the current ATS diagnostic cri-
teria [2], and we evaluated drug susceptibility, treat-
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Figure 1. Summary of the 2007 American Thoracic Society diagnostic criteria
ment regimens, and outcome. In addition, we analyzed the
genotypes of all clinical isolates that were evaluated, to study
the molecular epidemiology of M. szulgai in The Netherlands.
METHODS
To determine clinical relevance, we examined the medical re-
cords of all patients in The Netherlands from whom M. szulgai
was isolated between January 1999 and January 2006. We re-
corded sex, age, predisposing factors, symptoms, chest imaging
results, treatment and outcome, drug susceptibility, and status
in accordance with the diagnostic criteria of the ATS [2]. We
defined cure as clinical and radiographic improvement during
treatment and absence of positive culture results after comple-
tion of treatment.
In all patients, the isolates were subjected to laboratory di-
agnosis by the Dutch National Institute for Public Health and
the Environment (RIVM; Bilthoven, The Netherlands) or a self-
sufficient hospital laboratory. All self-sufficient hospitals used
16S rDNA gene sequence analysis for identification and granted
access to their databases, to ensure full national coverage. The
RIVM is the national reference laboratory that performs iden-
tification, drug susceptibility testing, and epidemiological typ-
ing of mycobacterial isolates for all hospitals in The Nether-
lands. At the RIVM, we used 16S rDNA gene sequence analysis
to identify mycobacteria, after ruling out the M. tuberculosis
complex with a Hain GenoType MTBC strip (Hain Lifescience)
or the more common species of NTM with an INNO-LiPA
Mycobacteria v2 (Innogenetics) reverse line-blot. M. szulgai is
not incorporated in this line-blot.
We used the agar dilution method for drug susceptibility
testing. Drugs tested were isoniazid, rifampicin, ethambutol,
streptomycin, cycloserine, prothionamide, amikacin, ciproflox-
acin, clofazimine, clarithromycin, and rifabutin [8].
Genotypes were determined using random amplified poly-
morphic DNA (RAPD) fingerprinting [9]. We selected OPA2,
OPA18, and IS986 as primers. The study was approved by the
regional ethics committee.
RESULTS
Files were reviewed for 21 patients. The patients’ clinical char-
acteristics are detailed in table 1. Sixteen patients (76%) met
the current ATS diagnostic criteria and therefore we considered
them to have M. szulgai disease. Eighteen patients (86%) were
male, and 20 (95%) were of Dutch origin; the mean age was
56 years. Most primary M. szulgai isolates were obtained from
pulmonary samples (sputum samples, 7 isolates [33%]; bron-
choalveolar lavage fluid samples, 8 isolates [38%]). Remaining
primary isolates were obtained from skin specimens (2 isolates
[10%]) and from feces, joint aspirate, lymph node biopsy, and
pleural fluid samples (1 isolate each [5%]). Primary samples
tested positive for acid-fast bacilli by direct microscopy for just
4 patients (19%). There were no relapses of prior M. szulgai
disease. Remarkably, 3 patients had a history of Billroth II
gastrojejunostomy; all 3 had M. szulgai disease. Impaired sys-
temic immunity was associated with extrapulmonary disease
(OR, 4.0; 95% CI, 1.71–9.35; ) but not with true dis-Pp .006
ease overall ( ).Pp .647
Of the 15 patients with pulmonary isolates (patients 7–21),
11 (73%) had true disease (table 1). Thirteen patients (87%)
were male, and all were of Dutch origin; the mean age was 60
years. Twelve patients (80%) had preexisting pulmonary dis-
ease, mostly COPD (10 patients [67%]), and 11 patients (73%)
were current or past smokers. Impaired immunity was noted
in 2 patients (diabetes for one patient and use of TNF-a–
neutralizing agents for the other).
Reported symptoms included productive cough (14 patients
[93%]), hemoptysis (4 patients [27%]), dyspnea (8 patients
[53%]), weight loss (8 patients [53%]), and fever and malaise
(6 patients for each [40%]). All patients underwent chest ra-
diography, and abnormalities were noted in 14 patients. Infil-
trates (7 patients [47%]), cavities (6 patients [40%]), bron-
chiectasis (3 patients [20%]), nodular opacities (1 patient
[7%]), pleural thickening (4 patients [27%]), and scars due to
previous lung disease (7 patients [47%]) were observed. In 10
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patients, additional CTs of the thorax were performed, revealing
1 additional case of cavitary disease and 1 additional case of
nodular bronchiectatic disease (in patients 7 and 20, respec-
tively) (table 1). All other CT findings were concomitant with
the findings on the chest radiograph.
Six patients (patients 1–6) had M. szulgai isolates recovered
from extrapulmonary sites (table 1). Five (83%) of the 6 pa-
tients met the ATS diagnostic criteria, having skin (2 patients)
and joint, intestinal, and lymph node infections (1 patient
each). The skin, joint, and intestinal diseases represented dis-
seminated disease. Five patients (83%) were male, and 5 (83%)
were of Dutch origin; the mean age was 44 years. Predisposing
conditions were HIV infection (2 patients [33%]), IFN-g re-
ceptor deficiency (2 patients [33%]), and receipt of high-dose
steroid treatment (1 patient [17%]). Aside from local signs and
symptoms, which are detailed in table 1, patients reported pro-
ductive cough (3 patients [50%]), dyspnea (4 patients [67%]),
malaise (3 patients [50%]), and weight loss (2 patients [33%]).
Three patients had abnormalities noted by chest radiography
that consisted of nodular opacities in 2 patients (patients 4 and
6) and an infiltrate and pleural fluid collection in 1 patient
(patient 3). Similar findings were noted in additional CTs of
the thorax.
Reported symptoms and radiographic abnormalities were
not significantly associated with fulfillment of the ATS diag-
nostic criteria, neither overall nor specifically among patients
infected with pulmonary or extrapulmonary isolates.
A total of 12 patients received antimycobacterial treatment,
of whom 11 met the former ATS diagnostic criteria, which were
available during the studied period [10]. On average, treatment
lasted for 12 months (range, 6–26 months) and consisted of
rifampicin or rifabutin with ethambutol and clarithromycin
and/or a quinolone antibiotic. Two patients (patients 2 and 6)
received concurrent treatment with IFN-g because of a proven
underlying IFN-g–receptor deficiency. Follow-up sputum mi-
croscopy or culture during treatment was not performed at
regular intervals; 5 patients with pulmonary M. szulgai disease
were known to have negative culture results after 6 months of
treatment. Treatment outcomes are detailed in table 1; we re-
corded no failures or relapses. Two patients died: one died
during treatment, and the other died just after therapy (due to
HIV-related cryptococcal meningitis in one and lung cancer in
the other). The average duration of follow-up after treatment
was 42 months (range, 9–84 months). Three patients met the
former ATS diagnostic criteria but were not treated; 1 died, 1
refused treatment, and 1 experienced conversion of culture
results to negative. No signs of active NTM disease were noted
during the follow-up for patients who did not meet the ATS
criteria. Isolation measures were taken for 4 patients until PCR
results for M. tuberculosis complex were proven to be negative.
In vitro intermediate susceptibility to isoniazid (MIC, 0.5–
1 mg/mL) and susceptibility to all other compounds in the test
panel was noted for all isolates. The MICs for rifampicin,
ethambutol, and clarithromycin were 0.5–1, 2–5, and !2 mg/
mL, respectively.
Genotyping of the isolates from our study period revealed
little intrapatient and good interpatient variability (figure 2).
Four major groups of strains are apparent. No associations
between genotype and predisposing factors, patient origin, or
clinical relevance were observed. Clustering that potentially in-
dicates (pseudo-)epidemics or laboratory cross-contamination
was not recorded. Two patients (patients 14 and 15, represented
by lanes M and N in figure 2) had similar genotypes of M.
szulgai, which was cultured in different laboratories and during
different periods. They were not epidemiologically linked. In 1
patient (patient 5, represented by lanes W/X and Y in figure
2), 2 different M. szulgai strains were isolated; one sample
(shown in lane Y) was cultured from feces, whereas the others
(shown in lanes W and X) were from skin lesions.
DISCUSSION
M. szulgai isolation was found to be clinically relevant in 16
(76%) of the 21 patients included in this study. O’Brien et al.
[11] also reported a high rate of true M. szulgai infection (8
[57%] of 14 patients) in the first national survey from the
United States. The current ATS criteria state that “cultures
yielding M. szulgai almost always have a pathological signifi-
cance” [2, p. 401]; our findings are in accordance with this.
No specific determinants significantly associated with M. szulgai
disease were observed; the limited number of patients and the
observed comorbidities do not allow greater statistical certainty.
Previous literature on M. szulgai disease focused mainly on case
reports [1, 3–6, 12, 13]. To our knowledge, we report the largest
group of isolates examined thus far for their clinical relevance.
Still, we may have missed M. szulgai isolates, because 16S rDNA
gene sequencing is not a free service at the national reference
laboratory, whereas identification by the INNO-LiPA Myco-
bacteria v2 reverse-line blot method—which does not recognize
M. szulgai—is. However, few strains that are unidentifiable to
the species level by this method are not sequenced, on the basis
of an appraisal of the costs by the referring hospital. If cases
of M. szulgai isolation have been missed, they will thus be very
few. In addition, strains submitted for drug susceptibility testing
are always identified to the species level, with 16S rDNA se-
quencing applied as appropriate.
The rate of extrapulmonary disease (31% of all cases of M.
szulgai disease) was similar to that reported in prior
publications by Marks et al. [1] (43%), Benator et al. [3] (29%),
and Maloney et al. [12] (33%). This may reflect the degree of
impairment of immunity seen in this patient category, although
it might also be a species-specific phenomenon. We considered
1 positive pleural fluid culture for a patient with Streptococcus
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Figure 2. Random amplified polymorphic DNA (RAPD) genotyping results of 25 strains isolated from 19 patients. Four major strain types are
represented: lanes A–E, type 1; lanes F–R, type 2; lanes S–V, type 3; and lanes W–Y, type 4. No association with geographical region, clinical
relevance, or specific predisposing conditions exists. Limited intrapatient variability is noted for patients with 12-year intervals between follow-up
cultures (lanes A and B and lanes I and J). Patient 5 has 2 distinct types from different body sites (lanes W/X and Y). Anti-TNF, TNF-a–neutralizing
treatment; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus type 1; INFgRD, IFN-g receptor deficiency; RIVM, Dutch National
Institute for Public Health and the Environment.
pneumoniae pneumonia with pleural effusion to have been con-
taminated on the basis of the patient’s clinical and radiographic
improvement after receipt of treatment with penicillin, with
complete resolution of the pleural fluid collection. The stool
sample from 1 patient with HIV/AIDS was considered to be
representative of disseminated infection, as determined on the
basis of a low CD4 count, symptoms, and associated chest
radiography and CT abnormalities, which improved—as did
the patient’s symptoms—after the initiation of antimycobac-
terial therapy; both interpretations remain debatable, because
the pathway to diagnosis was not optimal.
The clinical and demographic features of our study group
are comparable to those in previous reports [1–5, 12, 13]. The
number of patients with previous Billroth II gastrojejunostomy
was an unexpected observation; gastric surgery has been rec-
ognized as a risk factor for the development of tuberculosis
[14]. Maloney et al. [12] reported 1 case of M. szulgai disease
with partial gastrectomy, smoking, and alcohol abuse as pre-
disposing factors. The 3 patients in our study also had multiple
predisposing factors: they were smokers, with AIDS, COPD,
and old age as individual risk factors. It remains controversial
whether gastric surgery is a predisposing condition or a result
of other predisposing conditions (e.g., heavy smoking and al-
cohol abuse) that cause gastric ulcers that require surgery. Con-
trary to reports of Mycobacterium avium complex or Myco-
bacterium abscessus pulmonary disease in the United States [2],
we noted pulmonary M. szulgai disease only in patients with
established predisposing conditions. This finding may reflect a
difference in the pathophysiology of infections with different
NTMs.
In our cohort, we observed a favorable treatment outcome
for all but 2 patients, and none of the cases in our study con-
stituted relapses of prior M. szulgai disease. Previous studies
recorded similar results, with the few relapses attributable to
noncompliance with drug treatment or receipt of an inadequate
drug regimen [1, 3, 12, 13]. Our findings imply that the ob-
served average treatment regimen—12 months of rifampicin,
ethambutol, and clarithromycin—leads to favorable outcomes
without bacteriological relapse. In vitro drug susceptibility test-
ing results supported this assumption. Randomized, controlled
trials are needed to investigate the optimal drug treatment and
its duration. We realize, however, that these studies are difficult
to perform, because they require a large, multiple-center ap-
proach to collect a large enough sample size. In our cohort,
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the treatment regimens were based on data from the available
literature or expert consultation [10]; the susceptibility of the
isolates to the most frequently used drugs did not necessitate
changes in therapy regimens.
We observed possible instances of both undertreatment (i.e.,
patients who met the diagnostic criteria were not treated) and
overtreatment (i.e., treatment of persons who did not meet
diagnostic criteria). This, as well as the lack of bacteriological
follow-up during treatment and handling of the uncertain cases
of extrapulmonary disease discussed above, could reflect a lack
of knowledge of and experience with the diagnosis and man-
agement of NTM disease in physicians or clinical circumstances
that were not captured in our file review. Both over- and un-
dertreatment can be harmful for patients.
The mostly unique genotypes imply acquisition of M. szulgai
from the local environment rather than human-to-human
transmission or laboratory contamination, as was found in pre-
vious studies [4, 7, 9]. The uncertain pathogenesis and envi-
ronmental reservoirs, as well as the low frequency of isolation,
are important drawbacks to these molecular epidemiological
studies and to the interpretation of their results. The absence
of an association between RAPD genotype and fulfillment of
the ATS diagnostic criteria may reflect the importance of pa-
tient—rather than mycobacterial—factors in the etiology of M.
szulgai disease. The limited intrapatient variability suggests
good reproducibility and persisting monoclonal infections. In
1 patient (patient 5), 2 infecting strains were found in speci-
mens from separate body sites (as denoted in lanes W/X and
Y in figure 2). The minor changes observed in serial isolates
may hint at either limited reproducibility of RAPD genotyping
or genetic drift of the infecting strain during chronic infection.
In conclusion, the vast majority (76%) of 21 patients with
M. szulgai isolates in our study experienced true M. szulgai
disease. Therefore, clinical M. szulgai isolation demands careful
follow-up. Extrapulmonary disease occurs in patients with im-
paired immunity. Stricter adherence to diagnostic guidelines
seems desirable. Treatment with rifampicin, ethambutol, and a
macrolide antibiotic leads to favorable outcomes; its optimal
duration, as well as the efficacy of alternative regimens, requires
additional study. M. szulgai is most likely contracted from the
environment, although this subject also requires further study.
Acknowledgments
Potential conflicts of interest. All authors: no conflicts.
References
1. Marks J, Jenkins PA, Tsukamura M. Mycobacterium szulgai—a new
pathogen. Tubercle 1972; 53:210–4.
2. Griffith DE, Aksamit T, Brown-Elliot BA, et al. An official ATS/IDSA
statement: diagnosis, treatment, and prevention of nontuberculous my-
cobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416.
3. Benator DA, Kan V, Gordin FM. Mycobacterium szulgai infection of
the lung: case report and review of an unusual pathogen. Am J Med
Sci 1997; 313:346–51.
4. Abalain-Colloc ML, Guillerm D, Sala¨un M, Gouriou S, Vincent V,
Picard B. Mycobacterium szulgai isolated from a patient, a tropical fish
and aquarium water. Eur J Clin Microbiol Infect Dis 2003; 22:768–9.
5. Tortoli E, Besozzi G, Lacchini C, Penati V, Simonetti MT, Emler S.
Pulmonary infection due to Mycobacterium szulgai: case report and
review of the literature. Eur Respir J 1998; 11:975–7.
6. Fang CT, Chang SC, Luh KT, Chang YL, Hsueh PR, Hsieh WC. Suc-
cessful treatment of disseminated Mycobacterium szulgai infection with
ciprofloxacin, rifampicin, and ethambutol. J Infect 1999; 38:195–7.
7. Portaels F. Epidemiology of mycobacterial diseases. Clin Dermatol
1995; 13:207–22.
8. van Klingeren B, Dessens-Kroon M, van der Laan T, Kremer K, van
Soolingen D. Drug susceptibility testing of Mycobacterium tuberculosis
complex using a high throughput, reproducible, absolute concentration
method. J Clin Microbiol 2007; 45:2662–8.
9. Zhang Q, Kennon R, Koza MA, Hulten K, Clarridge JE III. Pseudoe-
pidemic due to a unique strain of Mycobacterium szulgai: genotypic,
phenotypic, and epidemiological analysis. J Clin Microbiol 2002; 40:
1134–9.
10. Wallace RJ Jr, Glassroth J, Griffith DE, Olivier KN, Cook JL, Gordin
F; American Thoracic Society. Diagnosis and treatment of disease
caused by nontuberculous mycobacteria. Am J Respir Crit Care Med
1997; 156:S1–25.
11. O’Brien RJ, Geiter LJ, Snider DE Jr. The epidemiology of nontuber-
culous mycobacterial diseases in the United States. Am Rev Respir Dis
1987; 135:1007–14.
12. Maloney JM, Gregg CR, Stephens DS, Manian FA, Rimland D. Infec-
tions caused by Mycobacterium szulgai in humans. Rev Infect Dis
1987; 9:1120–6.
13. Yamamoto M. Pulmonary diseases due to Mycobacterium szulgai in
Japan. Intern Med 2000; 39:277–9.
14. Steiger Z, Nickel WO, Shannon GJ, Nedwicki EG, Higgins RF. Pul-
monary tuberculosis after gastric resection. Am J Surg 1976; 131:
668–71.
 at K
atholieke U
niversiteit on July 11, 2012
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
